All companies
GRAIL logo

What smart money is saying about GRAILUnited States flag

GRAL · Healthcare · Medical - Diagnostics & Research · Market cap $3.39B

1 fund in our archive has pitched GRAIL — most recently Granahan Investment Management Focused Growth Strategy in June 2026.

Company profile

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Get an email when a fund writes about it

Summarize with Warren AI
1
Reported positions
1
Bought
0
Sold
1
Letter

Position history

Every position in GRAIL on record in the archive was reported in Q2 2026, across 1 fund letter1 opened or added to the position.

Fund letters reporting a position in GRAIL, by quarter
QuarterLettersBoughtSoldTheses
Q2 20261101

Fund activity · 1 position · 1 move

Fund coverage · 1 thesis

  • Granahan Investment Management Focused Growth Strategy
    June 2026

    GRAIL is viewed as a biotech picks-and-shovels beneficiary of AI-driven progress in the sector.

    Read the full thesis

Read every full thesis on GRAIL

Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans
Share this ledger